LUMOS PHARMA, INC.
lumos-pharma.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2024 10-Q, filed Nov 7, 2024. Its latest SEC filing is a SCHEDULE 13G/A from Feb 13, 2025.
10-Q for Q3 FY2024, filed Nov 7, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops an oral growth-hormone drug candidate for children with pediatric growth hormone deficiency and other rare endocrine disorders.
10-K for FY2023, filed Mar 7, 2024After the consummation of the Merger, we have focused our efforts on the development of our sole product candidate, secretagogue ibutamoren…View ↗
Our pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (“GH”)…View ↗
If approved, LUM-201 has the potential to become the first approved oral GH secretagogue to treat rare endocrine disorders associated with…View ↗
How Did They Make Money?
$2.1M
-
10-K for FY2023, filed Mar 8, 2024
$2.1M ↗
Who Were Their Customers?
If approved, Lumos expects to market LUM-201 for rare-disease patients through a specialty sales organization, potentially with third parties’ sales and distribution systems; these patients are typically treated by a small number of specialists.
10-K for FY2023, filed Mar 7, 2024
Did Revenues Turn Into Profits?
No. It lost $34M in FY2023.
10-K for FY2023, filed Mar 8, 2024
10-K for FY2023, filed Mar 8, 2024
−$34MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2024, filed Nov 8, 2024
−$7.5MView ↗
- ▼ −10% (Loss)
- vs −$8.3M in Q3 FY2023
-
Dec 12, 2024
Lumos was acquired in a completed merger
Shares converted into cash consideration and a contingent value right; Lumos became a wholly owned subsidiary of Parent.
Sources
8-K, filed Dec 12, 2024
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on December 12, 2024, Merger Sub completed a…View ↗
Who Did They Compete With?
Competes with Novo Nordisk, Eli Lilly and, F. Hoffman-La Roche, Genentech, Pfizer, Merck Serono, Teva Pharmaceuticals Industries, Sandoz, LG Life Science, Biopartners, Ferring Pharmaceuticals, Ascendis Pharma, and OPCO Health
10-K for FY2023, filed Mar 7, 2024We are developing our product candidate, LUM-201, for treatment of a subset of PGHD patients based on a once daily weight-based oral dosing…View ↗
Loading...
